Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 5
Submit an article Journal homepage
261
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir

Tamar Tadmora Hematology Unit, Bnai Zion Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, IsraelCorrespondence[email protected]
View further author information
,
Guy Melamedb Kahn Sagol Maccabi (KSM) Research & Innovation Center and Maccabi tech Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, IsraelView further author information
,
Tal Patalonb Kahn Sagol Maccabi (KSM) Research & Innovation Center and Maccabi tech Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, IsraelView further author information
,
Hilel Alapib Kahn Sagol Maccabi (KSM) Research & Innovation Center and Maccabi tech Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, IsraelView further author information
&
Lior Rokachc Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Beer-Sheva, IsraelView further author information
Pages 1054-1056 | Received 14 Jan 2023, Accepted 19 Feb 2023, Published online: 13 Mar 2023

References

  • Deo R, Choudhary MC, Moser C, et al. Viral and symptom rebound in untreated COVID-19 infection. medRxiv. Aug 2., 2022;
  • Epling BP, Rocco JM, Boswell KL, et al. COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir. medRxiv. 2022; Jun 17;2022.06.16.22276392.
  • Parums DV. Editorial: rebound COVID-19 and cessation of antiviral treatment for SARS-CoV-2 with paxlovid and molnupiravir. Med Sci Monit. 2022;28:e938532.
  • Anderson AS, Caubel P, Rusnak JM. Investigators E-HT. Nirmatrelvir-Ritonavir and viral load rebound in covid-19. N Engl J Med. 2022;387(11):1047–1049.
  • Centers for Disease Control and Prevention (CDC). CDC health alert network. Health advisory. COVID-19 rebound after Paxlovid treatment; 2022, May 24. Available from: https://emergency.cdc.gov/han/2022/pdf/CDC_HAN_467.pdf.
  • Rubin R. From positive to negative to positive Again-The mystery of why COVID-19 rebounds in some patients who take paxlovid. JAMA. 2022;327(24):2380–2382.
  • Wang L, Berger NA, Davis PB, et al. COVID-19 rebound after paxlovid and molnupiravir during January–June 2022. medRxiv. 2023 Feb 8;76(3):e530–e532; Jun 22;2022.06.21.22276724.
  • Tadmor T, Alapi, H, Rockach . Effectiveness of nirmatrelvir plus ritonavir treatment for patients with chronic lymphocytic leukemia during the omicron sur. 2023, blood, accepted for publication.
  • Carlin AF, Clark AE, Chaillon A, et al. Virologic and immunologic characterization of COVID-19 recrudescence after nirmatrelvir/ritonavir treatment. Clin Infect Dis. 2022;

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.